University of Pennsylvania Perelman School of Medicine and Yale University School of Medicine, along with other collaborators ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results